Jeena Sikho Lifecare Q3 FY26 Earnings Call Transcript Released
Jeena Sikho Lifecare reported Q3 FY26 results with operational income at ₹221.7 Cr (up 92% YoY) and EBITDA at ₹100.8 Cr (up 240% YoY). PAT was ₹66.7 Cr (up 400% YoY). The company is expanding its bed capacity and launching new health products and a health card. International expansion is underway in UAE, Kazakhstan, and Nepal.
The announcement details significant financial growth, expansion plans, and new product strategies, which are material to investors and indicate strong future prospects for the company.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with significant increases in operational metrics and plans for new product launches and international expansion, indicating positive financial and business performance.
Jeena Sikho Lifecare Limited has released the transcript of its Earnings Conference Call held on February 9, 2026, discussing the Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Months Ended December 31, 2025.
During the call, Managing Director Manish Grover highlighted a strong financial and operational performance for Q3 FY26. Total operational income reached ₹221.7 crores, a 92% year-on-year increase and 17% quarter-on-quarter growth. EBITDA crossed ₹100 crores for the first time, reaching ₹100.8 crores, with a margin of over 45%. Profit after tax stood at ₹66.7 crores, a 400% year-on-year increase, with a PAT margin of 30%.
Operational metrics showed significant growth: OPD and video consultations increased by 247% to 4.34 lakh patients, IPD patients grew by 84%, and day care patients rose by 139%. The company is expanding its bed capacity, with around 2,700 to 2,800 beds under development. The upcoming launch of the Jeena Sikho Health Card aims to enhance patient loyalty and promote Ayurveda. The company also plans to launch several new Ayurvedic products, with a target of 16 products by the end of 2026.
CFO Nanak Chand reiterated the financial highlights, noting a gross profit of ₹197.5 crores and a gross margin of 89%. Basic EPS for the quarter was ₹5.37. The company emphasized its strong balance sheet and capital-light expansion strategy.
Discussions during the Q&A session covered product launch strategies, bed occupancy rates (58% in Q3 FY26), capex per bed (₹3-4 lakhs), and international expansion plans including new centers in UAE, Kazakhstan, and Nepal. The company also detailed its new chain of 'Super Specialty Clinic Day Care Centers' within India and discussed the progress of its diagnostic business through the Chandan deal, aiming for ₹10-15 crores turnover from diagnostics. The company finalized an agreement with Entero for its OTC products, aiming to reach approximately 1 lakh medical stores.
Management expressed confidence in continuous growth and delivering value to stakeholders, with a focus on research and evidence-based work to support Ayurveda's global recognition. The company is also enhancing its VVIP wellness offerings and upgrading its resort in Meerut.
What to do with a filing like this
Jeena Sikho Lifecare Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jeena Sikho Lifecare Limited. Read the original for the full detail.